Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
K., Kanikarla-Marie, P., Warden, C
( Another, Phase 2 randomized, double-blind, clinical trial that examined the efficacy and safety of CNM-Au8 in subjects having early symptoms of ALS (NCT04098406) and already receiving steady background therapy, such as riluzole was conducted
doi:10.1017/S0007114513002730 Colman-Martinez M, Martinez-Huelamo M, Valderas-Martinez P, et al
Tolerability : The gradual titration schedules incorporated into licensed regimens already represent an evidence-based approach to minimising adverse effects whilst achieving therapeutic doses
US$ 29.02
US$ 28.89
US$ 19.99
US$ 20.08
US$ 26.34
US$ 27.28
US$ 25.31
US$ 29.59
US$ 24.23
